Brief: Dermapharm Posts FY Revenue in Line with Expectations

Dermapharm Holding SE

14/03/2023 06:33

Mar 14 (Reuters) - Dermapharm FY revenue EUR 1,025 million vs. estimate EUR
1,022 million.
* FY adjusted EBITDA margin 35.1%
* FY adjusted EBITDA EUR 360 million
* FY EBITDA EUR 331 million
* FY EBITDA margin 32.3%
* Outlook FY 2023 consolidated revenue between EUR 1,080 and 1,110 million
* Outlook FY 2023 adjusted consolidated EBITDA between EUR 300 and 310 million